

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: Up to 22 years old

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- All patients initiated on QUELIMMUNE therapy under the HDE-approved indication

Exclusion Criteria:

- Weight <10kg
- Age >22 years
- Known allergy to any components of QUELIMMUNE

Conditions & Interventions

Interventions:

DEVICE: QUELIMMUNE (SCD-PED)

Conditions:

Acute Kidney Injury, Acute Kidney Injury Due to Sepsis

Keywords:

continuous kidney replacement therapy, continuous renal replacement therapy, acute kidney injury, organ failure, inflammation, dialysis

More Information

Description:

QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥ 10 kg and age ≤ 22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator group of matched CKRT patients with sepsis who did not receive treatment with QUELIMMUNE

Contact(s): Ilham Boutahri - ilham.boutahri@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase:

IRB Number:

System ID: NCT06517810

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.